Transpharmation’s labs in Poland have new visitors. Danio rerio, more commonly known as zebrafish, have taken up residence to help develop a package of research methods enabling high-throughput screening of new substances with potential therapeutic effects in disorders of the central nervous system, including psychiatry disorders, neurodegenerative diseases, congenital defects, hereditary diseases, neuroimmunology and epilepsy. The model organism used in the first stage of screening will be a danio rerio embryo or larvae.
Due to its advantages, this organism has become a very popular model in biomedical research in recent years, including in research into human neurological disorders. The development of this research platform will enable a quick, low-cost screening of substances with a potential therapeutic effect, which does not require the use of higher organisms. Substances selected in this way can be used for further research with the higher organisms, including laboratory rodents. This project will be conducted in collaboration with the Faculty of Veterinary Medicine (Laboratory of Genomics and Transcriptomics) of the University of Warmia and Mazury in Olsztyn as a part of "Implementation doctorate program".
We are pleased that our doctoral student and Research Assistant at Transpharmation Poland, Małgorzata Aleksandra Mierzejewska M.Sc.Eng, is leading this study. Expertly supported by Professor Piotr Podlasz, DVM, PhD, a pioneer in the use of zebrafish as a model organism in scientific research in Poland. He is the creator of the first laboratory in Poland that uses zebrafish in scientific research.
This study is also supervised by Ewa Sokołowska, Head of Transpharmation Poland and Company Director. Ewa Sokołowska holds a PhD in neurobiology, has over 15 years of experience in working with rodent models gained across Europe in many notable postings.